Literature DB >> 8794300

Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein.

M Enami1, K Enami.   

Abstract

We have analyzed the mechanism by which the matrix (M1) protein associates with cellular membranes during influenza A virus assembly. Interaction of the M1 protein with the viral hemagglutinin (HA) or neuraminidase (NA) glycoprotein was extensively analyzed by using wild-type and transfectant influenza viruses as well as recombinant vaccinia viruses expressing the M1 protein, HA, or NA. Membrane binding of the M1 protein was significantly stimulated at the late stage of virus infection. Using recombinant vaccinia viruses, we found that a relatively small fraction (20 to 40%) of the cytoplasmic M1 protein associated with cellular membranes in the absence of other viral proteins, while coexpression of the HA and the NA stimulated membrane binding of the M1 protein. The stimulatory effect of the NA (>90%) was significant and higher than that of the HA (>60%). Introduction of mutations into the cytoplasmic tail of the NA interfered with its stimulatory effect. Meanwhile, the HA may complement the defective NA and facilitate virus assembly in cells infected with the NA/TAIL(-) transfectant. In conclusion, the highly conserved cytoplasmic tails of the HA and NA play an important role in virus assembly.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794300      PMCID: PMC190706     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Palmitylation of the influenza virus hemagglutinin (H3) is not essential for virus assembly or infectivity.

Authors:  H Jin; K Subbarao; S Bagai; G P Leser; B R Murphy; R A Lamb
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

2.  Mutations in the cytoplasmic tail of influenza A virus neuraminidase affect incorporation into virions.

Authors:  P Bilsel; M R Castrucci; Y Kawaoka
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

3.  Sendai virus M protein binds independently to either the F or the HN glycoprotein in vivo.

Authors:  C M Sanderson; H H Wu; D P Nayak
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

4.  An influenza virus temperature-sensitive mutant defective in the nuclear-cytoplasmic transport of the negative-sense viral RNAs.

Authors:  K Enami; Y Qiao; R Fukuda; M Enami
Journal:  Virology       Date:  1993-06       Impact factor: 3.616

5.  Influenza virus NS1 protein stimulates translation of the M1 protein.

Authors:  K Enami; T A Sato; S Nakada; M Enami
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Mutations at palmitylation sites of the influenza virus hemagglutinin affect virus formation.

Authors:  T Zurcher; G Luo; P Palese
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  Interactions of normal and mutant vesicular stomatitis virus matrix proteins with the plasma membrane and nucleocapsids.

Authors:  L D Chong; J K Rose
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

8.  A tyrosine-based motif in the cytoplasmic domain of the alphavirus envelope protein is essential for budding.

Authors:  H Zhao; B Lindqvist; H Garoff; C H von Bonsdorff; P Liljeström
Journal:  EMBO J       Date:  1994-09-15       Impact factor: 11.598

9.  The influenza virus hemagglutinin cytoplasmic tail is not essential for virus assembly or infectivity.

Authors:  H Jin; G P Leser; R A Lamb
Journal:  EMBO J       Date:  1994-11-15       Impact factor: 11.598

10.  Fine structure of influenza A virus observed by electron cryo-microscopy.

Authors:  Y Fujiyoshi; N P Kume; K Sakata; S B Sato
Journal:  EMBO J       Date:  1994-01-15       Impact factor: 11.598

View more
  71 in total

1.  Influenza virus matrix protein is the major driving force in virus budding.

Authors:  P Gómez-Puertas; C Albo; E Pérez-Pastrana; A Vivo; A Portela
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Restriction of viral replication by mutation of the influenza virus matrix protein.

Authors:  Teresa Liu; Zhiping Ye
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape.

Authors:  H Jin; G P Leser; J Zhang; R A Lamb
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

4.  Lipid rafts and pseudotyping.

Authors:  W F Pickl; F X Pimentel-Muiños; B Seed
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Generation of influenza A viruses with chimeric (type A/B) hemagglutinins.

Authors:  Taisuke Horimoto; Ayato Takada; Kiyoko Iwatsuki-Horimoto; Masato Hatta; Hideo Goto; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

6.  The morphology and composition of influenza A virus particles are not affected by low levels of M1 and M2 proteins in infected cells.

Authors:  Svetlana V Bourmakina; Adolfo García-Sastre
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Influenza B virus BM2 protein is transported through the trans-Golgi network as an integral membrane protein.

Authors:  Shinji Watanabe; Masaki Imai; Yoshiro Ohara; Takato Odagiri
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Cytoplasmic domain of influenza B virus BM2 protein plays critical roles in production of infectious virus.

Authors:  Masaki Imai; Kazunori Kawasaki; Takato Odagiri
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

9.  Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles.

Authors:  Benjamin J Chen; George P Leser; Eiji Morita; Robert A Lamb
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

10.  Introduction of a temperature-sensitive phenotype into influenza A/WSN/33 virus by altering the basic amino acid domain of influenza virus matrix protein.

Authors:  Teresa Liu; Zhiping Ye
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.